Evaluation of the Renal Safety of Direct Acting Antivirals in Chronic Hepatitis C Patients
Journal of Advances in Medical and Pharmaceutical Sciences,
Objective:Direct acting antivirals (DAA) is a class of antivirals that hasbeen extensively used in chronic hepatitis C virus (HCV) patients over the past 6 years.Despite the excellent therapeutic benefits of DAA, there is a knowledge gap regardingthe safety of this class. Several reports of possible renal toxicity associated with DAAadministration can be found in the literature. The aims of this study are: to assess therenal safety of DAA used for the treatment of chronic HCV infection and to quantify the odds ofdeveloping renaltoxicityin patients withchronicHCV viralinfection.
Study Design: Disproportionalityanalysiswasusedtodetectsignalsofpotentialsideeffects.
Place andDuration: Amman –Jordan,One year study since September 2017 to march 2018.
Methods: The method that was applied in the current study is obtaining the data from United States (US) food and drug administration(FDA)adverseeventreportingsystem(FAERS).DatabetweenJuly,2014andSeptember,2017werecombinedandexplored.Disproportionalityanalysiswasconducted to reports from chronic HCV patients to explore possible association betweenDAA administrationand renalsideeffects.
Results: This study showed that a total of 3,837,418 safety reports were available in the period between July,2014 and September, 2017. Patients with chronic HCV infection represent 22,022 cases.When considering all DAA as drug of interest, the use of DAA alone or in combinationwith interferon and/or ribavirin did not increase the risk of having renal side effects.Exploring individual DAA demonstrated a significant association between the incidenceofrenalsideeffectsandtheadministrationoftelapreviranddasabuvir.ConsideringrenalsideeffectsindividuallyshowedasignificantassociationbetweenDAAadministrationand chronickidney disease.
Conclusions: In this study, we reported a significant association between DAA administration andchronic kidney disease and between telaprevir or dasabuvir and renal side effect. Thesefindings are used for hypothesis generation rather than testing.
- Adverse drug reactions reporting systems
- hepatitis C
- direct acting antiviral
How to Cite
Hoofnagle, Course and outcome of hepatitis C. Hepatology 36(5 Suppl 1):S21– S29.
WaldemarHalota, Robert Flisiak, JacekJuszczyk, Piotr Małkowski, MałgorzataPawłowska, Krzysztof Simon,TomasiewiczK., Recommendations for the treatment of hepatitis C in 2017. Clinical and Experimental Hepatology;2017.
Strader DB1, Wright T, Thomas DL, Seeff LB, Diagnosis AASLD practice guideline : Diagnosis, management, and treatment of hepatitis C. Hepatology;2004.
Schinazi R, Halfon P, Marcellin P, AT. HCV direct-acting antiviral, agents :The best interferon-free combinations. Liver Int.2014;34(Suppl 1):69-78.
Yee GC, Talbert RL, Matzke GR, DiPiro JT, Wells BG, Posey LM. Pharmacotherapy: A pathophysiologic approach, tenth edition, mcgraw-hill education; 2016.
AASLD-IDSA, HCV Guidance: Recommendations for testing, managing, and treating hepatitis C;2017.
accessed on Dec 4, 2017, 2017(December 4).
Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, R. Stern AF,Stättermayer R, Stauber M,Strasser,ZollerH. DAA‐based antiviral treatment of patients with chronic hepatitis C in the pre‐and postkidney transplantation setting. Transplant International.2016;29(9):999-1007.
Chayama K. Hepatitis C virus treatment: Highly effective therapy with direct acting antivirals and associated viral resistance, springer Singapore; 2016.
Chen K, Lu P, Song R, Zhang J, Tao R, Wang Z, Zhang W,GuaM.Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection. Medicine.2017;96(30):E7568.
Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stättermayer AF, Stauber R, StrasserM,ZollerH. DAA‐based antiviral treatment of patients with chronic hepatitis C in the pre‐and postkidney transplantation setting. Transplant International.2016;29(9):999-1007.
Jones SC, Meyer T, Brinker A. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus; 2017.
Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, Horita T, YasudaS, Koike T. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: Risk analysis in Hepatitis B surface antigen-negative cases. The Journal of Rheumatology.2011;38(10):2209-2214.
Reddy N,SavaniB. Hepatitis B reactivation in patients with hematological malignancies and stem cell transplantation. J. Blood Lymph.2013;4:114.
Hoofnagle JH. Reactivation of hepatitis B. Hepatology.2009;49(5 Suppl):S156-65.
Ashraf T, MajoniW. Acute interstitial nephritis associated with sofosbuvir and daclatasvir. ACG Case Reports. 2017;4:e84.
George. Reporting adverse drug reactions: a guide for healthcare professionals. British Medical Association; 2006.
McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, ea,Hazell L.AdversedrugreactionreportingintheUK:aretrospectiveobservationalcomparison of yellowcard reportssubmitted bypatientsand healthcare professionals.DrugSafety.2010;33:775-788.
FDA. Food and drug administration office of drug safety annual report; 2001.
Rave Harpaz, William DuMouchel, Paea LePendu1, Anna Bauer-Mehren1, Patrick Ryan3,aN, Shah H. Performance of pharmacovigilance signal detection algorithmsfortheFDAadverseeventreportingsystemclinicalpharmacologic; 2013.
Yun Mi Yu1, Euni Lee, Bon Sun Koo, KyeongHyeJeong, Kyung Hee Choi, Lee KyungKang, Mo Se Lee, KwangHoon Choi, Oh1 JM, Wan Gyoon Shin. Predictivefactorsofspontaneousreportingofadversedrugreactionsamongcommunitypharmacists.2016;10:137.
WHO. World health association, Pharmacovigilance;2018.
Poluzzi E, Raschi E, PiccinniC, De PontiF. Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA adverse event reporting system (AERS). Data mining applications in engineering and medicine, InTech; 2012.
Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, MooreN, De PontiF. Liver injury with novel oral anticoagulants: Assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system. British journal of clinical pharmacology.2015;80(2):285-293.
Abstract View: 124 times
PDF Download: 70 times